Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06RUK
|
||||
| Former ID |
DIB013138
|
||||
| Drug Name |
Combotox
|
||||
| Synonyms |
IMTOX 22; Anti CD22/N97A; Anti CD22/ricin; Anti CD19 + anti CD22/N97A; Ricin-conjugated anti-CD22 and anti-CD19; IgG-RFB4-dgA and IgG-HD37-dgA
|
||||
| Indication | Leukemia [ICD9: 208.9; ICD10:C90-C95] | Phase 1 | [548715] | ||
| Company |
University of Texas Southwestern Medical Center
|
||||
| Target and Pathway | |||||
| Target(s) | B-cell receptor CD22 | Target Info | Modulator | ||
| B-lymphocyte antigen CD19 | Target Info | Modulator | |||
| NetPath Pathway | IL-7 Signaling Pathway | ||||
| PANTHER Pathway | B cell activationP00010:B cell activation | ||||
| Pathway Interaction Database | BCR signaling pathwaybcr_5pathway:BCR signaling pathway | ||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-1257604:PIP3 activates AKT signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.